 |
Edward A. Kesicki, PhD
Director, Small-Molecule Drug Discovery
Ed Kesicki is the Director of Small-Molecule Drug Discovery
at IDRI.
He is involved with two key areas of research within the organization. First, he oversees the design and synthesis of new small-molecule antibiotics for tuberculosis treatment. Second, he is designing processes to prepare fully synthetic vaccine adjuvants that act via Toll-like receptors in order to stimulate the immune system during vaccination.
An organic chemist by training,
Ed has been in the drug discovery business since 1997. Ed cofounded
the nonprofit Afya World Medicines, which was
merged into IDRI in 2008 to focus on the discovery of
new treatments for tuberculosis. Prior to Afya, Ed spent 9
years at Icos Corporation, working on several medicinal
chemistry projects that delivered compounds that
are currently in human studies
(Chk1 kinase and PI3-kinase delta inhibitors). Ed is
an inventor on over 20 patents in 5 target areas, an author
on numerous peer-reviewed articles, and has been invited to
speak at several national meetings.
Ed received his BS from Stanford University and earned his
PhD in Organic Chemistry from the University of California,
San Diego.
|
